The effectiveness and safety of the use of ethylmethylhydroxypyridine of succinate in patients with acute ischemic stroke

Authors:
M.V. Zhuravleva ^1.2 , I.A. Schukin ³ , M.S. Fidler ³ , A.B. Prokofiev ^1.2 , S.Yu. Serebrova ^1.2 , N.S. Vasyukova ⁴ , E.Yu. Demchenkova ¹ , V.V. Arkhipov ¹

¹ FSBI “Scientific Center for Expertise of Medical Application” of the Ministry of Health of Russia, Moscow, Russia;
² FGAOU VO "First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University), Moscow, Russia;
³ FGAOU in Russian National Research Medical University named after N.I. Pirogov ", Moscow, Russia;
⁴ FGBNU "Federal Scientific Center-the All-Russian Research Institute of Experimental Veterinary Medical Academy of Education named after K.I. Scriabin and Ya.R. Kovalenko of the Russian Academy of Sciences ", Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 12, Issue. 2

Summary:
the stroke remains one of the most urgent problems of modern medicine, which is leading the cause of mortality and disability. In the Russian Federation there is extensive experience in the use of neurocytoprotectors in ischemic stroke. In real clinical practice, it is important to observe the conditions under which neuroprotement will be as safe and effective as possible. This review presents an analysis of the results of clinical studies devoted to the effectiveness and safety of ethylmethylhydroxypyridine of succinate (Mexidol) in patients with acute ischemic stroke. Early (in the first 6 hours of stroke), the use of the drug significantly improves recovery dynamics and improves the outcome of the disease; When using the drug, the acceleration of regression of neurological disorders, improvement of the life and quality of life of patients was noted. The studies showed a high security profile of ethylmethylhydroxypyridine of succinate. Keywords: ischemic stroke, thrombolytic therapy, clinical studies, disability, antioxidant system, ethylmethydlhydroxypirinatin, Mexidol.